Core Viewpoint - The announcement highlights the completion of the first patient enrollment in the global multi-center Phase II clinical trial of CS2009, a novel tri-specific antibody targeting PD-1, VEGFA, and CTLA-4, by the company [1] Group 1: Clinical Trial Progress - The Phase II clinical trial of CS2009 is actively enrolling patients in Australia and China, with plans to expand to the United States in the future [1] - The first patient has been enrolled in Australia, marking a significant milestone in the trial [1] Group 2: Product Overview - CS2009 is a tri-specific antibody developed independently by the company, designed to target PD-1, VEGFA, and CTLA-4, aiming to achieve multi-dimensional anti-tumor effects [1] - The antibody has the potential to be a first-in-class or best-in-class treatment due to its differentiated molecular design [1] Group 3: Mechanism and Disease Coverage - CS2009 can reactivate exhausted tumor-infiltrating T cells and has neutralizing capabilities comparable to existing anti-VEGF antibodies [1] - The product has a broad disease coverage, including but not limited to non-small cell lung cancer, small cell lung cancer, liver cancer, gastric cancer, ovarian cancer, cervical cancer, breast cancer, colorectal cancer, and esophageal cancer [1]
基石药业-B(02616)：CS2009(PD-1/VEGF/CTLA-4三特异性抗体)II期临床试验于澳大利亚完成首例患者入组